Pain Market Research Reports & Industry Analysis
In considering the IASP definition, it is important to note that not all potentially tissue-damaging stimuli result in pain. Nociception is the activation of the primary afferent nerves with peripheral terminals that respond differently to noxious stimuli. Nociceptors function primarily to sense and transmit pain signals. Nociception may or may not be perceived as pain, depending on a complex interaction within the nociceptive pathways. If nociceptive stimuli are blocked, pain is not perceived. Finally, it is important to distinguish pain, or nociception, from suffering. Suffering is the state of severe distress associated with events that threaten the intactness of the person. Suffering is an emotion. Pain and suffering are not the same phenomenon.
The person who complained of pain in the heart because of the death of a loved one is suffering rather than experiencing pain as it is defined by the IASP. It is clear that three conditions could exist: 1) suffering occurs in the presence of pain,2) suffering occurs when pain is not present, and 3) pain occurs when suffering is not present. For example, the woman awaiting breast biopsy may suffer because of anticipated loss of her breast. After the biopsy, she may have pain without suffering if the biopsy is negative or pain with suffering if the biopsy is positive for malignancy. Interventions aimed at relieving pain and suffering may have some commonalities, but clearly some interventions for suffering will be inadequate for pain just as some interventions for pain are inadequate for suffering.
Pain Industry Research & Market Reports
-
Veterinary Pain Management Market Report by Product (Drugs, Devices), Animal Type (Companion, Livestock), Application (Osteoarthritis and Joint Pain, Postoperative Pain, Cancer, and Others), End User (Hospitals and Clinics, and Others), and Region 2025-2033
... 2025-2033. There are several factors that are driving the market, which include the rising number of pet parents, various regulatory approvals, and increasing prevalence of chronic diseases such as arthritis, cancer, joint pain, and post-surgical ... Read More
-
Neuromodulation Market Report by Technology (Internal Neuromodulation, External Neuromodulation), Biomaterial (Metallic Biomaterials, Polymeric Biomaterials, Ceramic Biomaterials), Application (Parkinson's Disease, Epilepsy, Depression, Dystonia, Pain Management, and Others), and Region 2025-2033
... market is experiencing robust growth, driven by the increasing prevalence of chronic and neurological disorders, imposition of favorable regulatory environment, rising expenditure on healthcare, significant advancements in device technology, and growing demand for minimally invasive ... Read More
-
Global Osteonecrosis Treatment Market - 2025-2033
... also referred to as avascular necrosis, aseptic necrosis, or ischemic bone necrosis, is a degenerative bone condition caused by the interruption of blood flow to the bone's subchondral area, leading to the death of bone ... Read More
-
2025 Global: Hip Osteoarthritis Pain Drug Market - Innovative Markets Forecast (2031) report
... accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2020 to 2031 using regression analysis in our modeling. and Perry/Hope is the only ... Read More
-
Global Cannabidiol (CBD) Market 2025-2029
... provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors. The report offers an up-to-date analysis regarding the current market scenario, the latest ... Read More
-
Pain Management Devices And Therapies Global Market Report 2025
... management devices and therapies market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond. Reasons to Purchase Gain ... Read More
-
Global Pain Management Drugs Market - 2025-2033
... drugs, also called analgesics, are medications aimed at alleviating pain. These are classified into several categories, including non-steroidal anti-inflammatory drugs (NSAIDs), opioids, corticosteroids, muscle relaxants, anticonvulsants, etc. NSAIDs are commonly used for mild to moderate ... Read More
-
In-vivo CRO Market Report by Type (Rodent, Non-Rodent), GLP Type (Non-GLP, GLP Toxicology), Indication (Autoimmune/Inflammation Conditions, Pain Management, Oncology, CNS Conditions, Diabetes, Obesity, and Others), and Region 2025-2033
... The growing prevalence of chronic diseases worldwide and the increasing R&D expenditure by pharmaceutical companies are propelling the market growth. In-vivo contract research organizations (CROs) are institutions that conduct extensive biopharmaceutical research on a contractual ... Read More
-
Transdermal Scopolamine
... CAGR of 5.3% over the analysis period 2024-2030. The U.S. Market is Estimated at US$141.9 Million While China is Forecast to Grow at 5.1% CAGR The Transdermal Scopolamine market in the U.S. is estimated at ... Read More
-
Nanocapsules
... 6.3% over the analysis period 2024-2030. Oncology, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$2.0 Billion by the end of the analysis period. Growth in ... Read More
-
Opioids
... 2.3% over the analysis period 2024-2030. Extended-Release / Long-Acting, one of the segments analyzed in the report, is expected to record a 2.9% CAGR and reach US$18.7 Billion by the end of the analysis period. ... Read More
-
Cancer Supportive Care
... at a CAGR of 2.2% over the analysis period 2024-2030. Opioids, one of the segments analyzed in the report, is expected to record a 2.3% CAGR and reach US$11.1 Billion by the end of the ... Read More
-
Cervical Pillows
... CAGR of 5.4% over the analysis period 2024-2030. Standard Cervical Pillows, one of the segments analyzed in the report, is expected to record a 5.5% CAGR and reach US$2.8 Billion by the end of the ... Read More
-
Chronic Spinal Cord Injury- Pipeline Insight, 2025
... nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered Global coverage Chronic Spinal ... Read More
-
Migraine Drugs
... CAGR of 16.0% over the analysis period 2024-2030. Acute Treatment, one of the segments analyzed in the report, is expected to record a 16.6% CAGR and reach US$7.2 Billion by the end of the analysis ... Read More
-
Cold Pain Therapy
... at a CAGR of 4.3% over the analysis period 2024-2030. OTC Products, one of the segments analyzed in the report, is expected to record a 4.5% CAGR and reach US$1.9 Billion by the end of ... Read More
-
Ulcerative Colitis Therapeutics
... at a CAGR of 4.3% over the analysis period 2024-2030. Oral, one of the segments analyzed in the report, is expected to record a 3.8% CAGR and reach US$5.6 Billion by the end of the ... Read More
-
Pain Management Devices
... at a CAGR of 7.8% over the analysis period 2024-2030. Neurostimulation Devices, one of the segments analyzed in the report, is expected to record a 8.4% CAGR and reach US$3.5 Billion by the end of ... Read More
-
Fibromyalgia Therapeutics
... CAGR of 2.9% over the analysis period 2024-2030. Antiepileptics, one of the segments analyzed in the report, is expected to record a 2.8% CAGR and reach US$2.1 Billion by the end of the analysis period. ... Read More
-
Scoliosis Management
... CAGR of 4.1% over the analysis period 2024-2030. Thoracolumbosacral Orthosis (TLSO), one of the segments analyzed in the report, is expected to record a 4.3% CAGR and reach US$3.2 Billion by the end of the ... Read More
-
Radiofrequency Ablation Devices for Pain Management
... reach US$1.4 Billion by 2030, growing at a CAGR of 9.9% over the analysis period 2024-2030. Disposable Products, one of the segments analyzed in the report, is expected to record a 9.9% CAGR and reach ... Read More
-
Non-opioid Pain Patch
... at a CAGR of 2.2% over the analysis period 2024-2030. Lidocaine Patches, one of the segments analyzed in the report, is expected to record a 2.6% CAGR and reach US$1.5 Billion by the end of ... Read More
-
Women's Health Rehabilitation Products
... 2030, growing at a CAGR of 1.2% over the analysis period 2024-2030. Orthopedic Rehabilitation Products, one of the segments analyzed in the report, is expected to record a 2.2% CAGR and reach US$731.9 Million by ... Read More
-
Veterinary Pain Management
... at a CAGR of 7.9% over the analysis period 2024-2030. Drugs, one of the segments analyzed in the report, is expected to record a 8.2% CAGR and reach US$2.1 Billion by the end of the ... Read More
-
Neuromodulation
... 9.2% over the analysis period 2024-2030. Spinal Cord Stimulation, one of the segments analyzed in the report, is expected to record a 9.2% CAGR and reach US$5.4 Billion by the end of the analysis period. ... Read More
Research Assistance
